Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 3 8Phase EARLY_PHASE1 3Phase 4 3Phase 1/2 3Phase 1 2

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Recurrence 1Neoplasms 1Melanoma 1Fractures, Spontaneous 1Breast Neoplasms 1Bone Cysts, Aneurysmal 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Denosumab × Clear all
NCT06374459 2026-04-20

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Washington University School of Medicine

Phase 1/2 Recruiting
152 enrolled
Breast

Breast Neoplasms

NCT03161756 2022-04-07

CHARLI

Melanoma and Skin Cancer Trials Limited

Phase 1/2 Unknown
72 enrolled
Dermatologic

Melanoma

NCT03415477 2018-01-30

Deno-ABC

Peking University People's Hospital

Phase 1/2 Completed
6 enrolled

Fractures, Spontaneous, Neoplasms, Recurrence, Bone Cysts, Aneurysmal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡